<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992716</url>
  </required_header>
  <id_info>
    <org_study_id>SKNt-001-CP4</org_study_id>
    <secondary_id>2017-001972-46</secondary_id>
    <nct_id>NCT03992716</nct_id>
  </id_info>
  <brief_title>Reaching Protein Target With SmofKabiven® Extra Nitrogen vs Olimel N9E During the Early Phase of Acute Critical Illness</brief_title>
  <official_title>Reaching Protein Target With SmofKabiven® Extra Nitrogen Versus Olimel N9E: A Prospective, Randomised, Active-controlled, Patient-blinded, Multicentre Clinical Trial During the Early Phase of Acute Critical Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Kabi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main focus of the study is to show that SmofKabiven® extra Nitrogen, in a realistic
      clinical setting, enables to meet high protein requirements in patients during the first week
      after onset of critical illness, without risk of overfeeding with energy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients reaching ≥70% of the cumulative target for protein delivery from Study Day 2 through Study Day 6</measure>
    <time_frame>5 days</time_frame>
    <description>The cumulative target for protein delivery is 6.75 g/kg over 5 Study Days (based on a daily target of 0.75 g/kg/day on Study Day 2 and 1.5 g/kg/day on Study Days 3 through 6); 70% of the cumulative target for protein delivery is 4.73 g/kg.
The cumulative protein delivery is calculated as the cumulative intake of amino acids from study drug and protein from enteral or oral nutrition on Study Day 2 through Study Day 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of the cumulative target for protein delivery reached from Study Day 2 through Study Day 6</measure>
    <time_frame>5 days</time_frame>
    <description>Actual cumulative protein delivery (g/kg/5d) divided by 6.75 (g/kg/5d) and multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean cumulative protein delivery by parenteral, enteral, and oral nutrition from Study Day 2 through Study Day 6</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculated mean cumulative protein deficit during the period from Study Day 2 through Study Day 6</measure>
    <time_frame>5 days</time_frame>
    <description>The cumulative protein deficit is calculated as the cumulative target for protein delivery (6.75 g/kg/5d) minus the actual administered dose (g/kg/5d amino acids from study drug + g/kg/5d from enteral and oral nutrition.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean total cumulative energy intake from parenteral, enteral and oral nutrition and from non-nutritional sources during the 5-day treatment period (calculated for each day from Study Day 2 through Study Day 6)</measure>
    <time_frame>5 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to increase of daily enteral and oral nutrition intake above 20% of total energy target of 20 kcal/kg/d during the 5-day treatment period</measure>
    <time_frame>5 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean daily insulin dose during the 5-day treatment period</measure>
    <time_frame>5 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean cumulative insulin dose for the 5-day treatment period</measure>
    <time_frame>5 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean change from baseline in daily insulin dose (Study Day 2 through Study Day 6)</measure>
    <time_frame>5 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maximum single insulin dose during the 5-day treatment period</measure>
    <time_frame>5 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean maximum daily blood glucose value during the 5-day treatment period</measure>
    <time_frame>5 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean minimum daily blood glucose value during the 5-day treatment period</measure>
    <time_frame>5 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean blood glucose value during the 5-day treatment period</measure>
    <time_frame>5 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean change from baseline in mean daily blood glucose value (Study Day 2 through Study Day 6)</measure>
    <time_frame>5 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in SOFA score, calculated daily from Study Day 3 through Study Day 7</measure>
    <time_frame>5 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival time up to Study Day 28</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality up to Study Day 28</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length of stay in the ICU up to Study Day 28</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Re-admission to ICU up to Study Day 28</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ICU mortality up to Study Day 28</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Length of stay in the hospital up to Study Day 28</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Re-admission to hospital up to Study Day 28</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Hospital mortality up to Study Day 28</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Therapeutic Intervention Scoring System (TISS)-28 score (including individual item score, category score, and total score)</measure>
    <time_frame>Study Day 7</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of mechanical ventilation up to Study Day 28</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline of the Medical Research Council (MRC) sum score</measure>
    <time_frame>Study Day 7, and either on day of ICU discharge or on Study Day 28, whatever occurs first</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline of ICU Mobility Scale</measure>
    <time_frame>Study Days 7, 14, and 28</time_frame>
    <description>Reference for ICU Mobility Scale: Hodgson C, Needham Dale, Haines K, Bailey M, Ward A, Harrold M, Young P, Zanni J, Buhr H, Higgins A, Presneill J, Berney S. Feasibility and inter-rater reliability of the ICU Mobility scale. Heart Lung 2014; 43(1):19-24. Erratum. Heart Lung 2014;43(4):388.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>SmofKabiven® extra Nitrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parenteral nutrition with SmofKabiven® extra Nitrogen in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olimel N9E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Parenteral nutrition with Olimel N9E in a dosage to provide 10 kcal/kg/day on Study Day 2 and 20 kcal/kg/day on Study Days 3 through 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SmofKabiven® extra Nitrogen</intervention_name>
    <description>SmofKabiven® extra Nitrogen (Fresenius Kabi) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.</description>
    <arm_group_label>SmofKabiven® extra Nitrogen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olimel N9E</intervention_name>
    <description>Olimel N9E (Baxter) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.</description>
    <arm_group_label>Olimel N9E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years and &lt;90 years, male and female

          2. Critically ill, medical or surgical ICU patient

          3. Admitted to the ICU on the same day or the day before with a minimum expected ICU stay
             of 3 days

          4. Central venous access available for continuous infusion of the study drugs

          5. Sequential Organ Failure Assessment (SOFA) score ≥2

          6. Contraindication against enteral nutrition or limited tolerance to enteral nutrition
             and it is planned that patient receives ≥80% of the total target caloric intake from
             parenteral nutrition during the first 3 nutritional treatment days

          7. Written informed consent from the patient or the patient's legal representative or
             deferred written consent from the patient or patient's legal representative (deferred
             proxy consent)

        Exclusion Criteria:

          1. Contraindication against parenteral nutrition or inability to receive parenteral
             nutrition via central venous access

          2. Received parenteral nutrition within 7 days before randomisation

          3. It is planned that patient receives ≥20% of the total target caloric intake via
             enteral or oral nutrition and/or non-nutritional sources (glucose solution for drug
             dilution or lipids from propofol/clevidipine or citrate from continuous renal
             replacement therapy) during the first 3 nutritional treatment days

          4. Body mass index (BMI) &lt;18.5 kg/m2 or &gt;35 kg/m2

          5. Burn injury

          6. Any severe, persistent blood coagulation disorder with uncontrolled bleeding

          7. Any congenital errors of amino acid metabolism

          8. Uncontrolled hyperglycaemia despite insulin treatment

          9. Known hypersensitivity to fish, egg, soybean proteins, peanut proteins, or to any of
             the active substances or excipients contained in SmofKabiven® extra Nitrogen or Olimel
             N9E

         10. Known hypersensitivity to milk protein or to any other substance contained in
             Fresubin® Original

         11. Treatment-refractory cardiopulmonary or metabolic instability showing persistent or
             progressive worsening despite increased interventions, including severe pulmonary
             oedema, severe cardiac insufficiency, myocardial infarction, acute phase of
             circulatory shock, severe sepsis, embolism, haemodynamic instability, metabolic or
             respiratory acidosis, hypotonic dehydration, or hyperosmolar coma

         12. Severe renal dysfunction, defined as serum creatinine ≥2.0 times baseline or urine
             output &lt;0.5 mL/kg/h for ≥12 hours (Acute Kidney Injury stage ≥2; [KDIGO 2012]), and
             blood urea nitrogen (BUN) exceeding 2 x upper limit of normal (ULN)

         13. Severe liver failure with encephalopathy, including intoxication (e.g. paracetamol,
             death cap, golden chain) and/or liver enzymes (aspartate aminotransferase [AST],
             alanine aminotransferase [ALT], gamma glutamyl transferase [GGT]) or bilirubin
             exceeding 5 x ULN

         14. Oncologic disease with anticancer drug and/or radiation treatment incl. Hyperthermic
             Intraperitoneal Chemotherapy (HIPEC) during this Trial up to and including Study Day
             28

         15. Preceding transplantation causal for acute critical illness

         16. Hemophagocytic syndrome

         17. Pregnancy or lactation

         18. Receiving end-of-life-care

         19. Pathologically altered blood pH (arterial pH &lt;7.0), oxygen saturation (SaO2 &lt;80%), or
             carbon dioxide concentration (PaCO2 ≥80 mm Hg)

         20. Hyperlipidaemia or any disorder of lipid metabolism characterised by
             hypertriglyceridaemia (serum triglyceride levels &gt;4 mmol/L [&gt;350 mg/dL])

         21. Treatment-refractory, clinically significant major abnormality in the serum
             concentration of any electrolyte (sodium, potassium, magnesium, total calcium,
             chloride, inorganic phosphate)

         22. Administration of growth hormone including teduglutide within the previous 4 weeks
             before randomisation

         23. Invasive devices and procedures influencing metabolism and organ perfusion, e.g.
             extracorporeal membrane oxygenation (ECMO), continuous renal replacement therapy
             (CRRT), molecular absorbent recycling system (MARS), intra-aortic balloon pump (IABP)

         24. Receipt of the last dose of study drug in another interventional clinical trial within
             the previous 4 weeks before randomisation into this clinical trial

         25. Previous inclusion in the present study

         26. Any other known reason that may prevent a patient to take part in the study in
             accordance with local requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Bohe, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Département d'Anesthésie-Réanimation, Centre Hospitalier Lyon Sud, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petra Loedige, MD</last_name>
    <phone>+496172686</phone>
    <phone_ext>5237</phone_ext>
    <email>petra.loedige@fresenius-kabi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steffen Benzing, PhD</last_name>
    <phone>+496172686</phone>
    <phone_ext>7709</phone_ext>
    <email>steffen.benzing@fresenius-kabi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine, Département d'Anesthésie-Réanimation</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Hantala, MD</last_name>
      <phone>+3364309837</phone>
      <email>nicolas.hantala@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Klinik für Anaesthesiologie</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan J Schaller, MD, MHBA</last_name>
      <phone>+49 4140 9635</phone>
      <email>s.schaller@tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Wojewódzki Szpital Zespolony im. J. Śniadeckiego</name>
      <address>
        <city>Białystok</city>
        <zip>15-897</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Piotr Gałkin, MD</last_name>
      <phone>+48 601 39 71 39</phone>
      <email>piotr.galkin@anestezjolog.com.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 13, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

